Oncology

Emerging research explores how a wearable device may identify infection before symptoms appear, which treatments reduce hospitalizations, and who remains most at risk.

A new randomized trial in newly formed heterosexual couples investigated whether recent human papillomavirus vaccination protects individuals or their partners against transmission.

In a phase 3 trial, trastuzumab deruxtecan significantly extended overall survival compared with ramucirumab plus paclitaxel in previously treated patients, with manageable toxicity and mostly low-grade...

A large randomized trial found that mailing unsolicited fecal immunochemical test kits increased colorectal cancer screening rates among adults aged 45 to 49 compared with strategies requiring patients to...

The FDA approved Zongertinib for adults with unresectable or metastatic non-squamous NSCLC with HER2 (ERBB2) TKD activating mutations following prior systemic therapy.

New research shows how respiratory infections can awaken dormant cancer cells, while RSV vaccines and flu antivirals show clear protective effects.

A multilevel intervention improved human papillomavirus vaccine initiation and completion among most children aged 11 to 12 years, though the effect was limited for those living in under-resourced settings,...

A multicenter randomized trial has demonstrated that the NeuroSAFE technique significantly improves erectile function and accelerates early urinary continence recovery following robot-assisted radical...

The FDA announced on June 12 that it has approved pembrolizumab for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1.

A phase 3 trial confirms that combining ibrutinib with venetoclax yields superior measurable residual disease clearance, progression-free survival, and overall survival in patients with chronic lymphocytic...